Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach.

Breast cancer represents a life-threatening problem globally. The major challenge in the clinical setting is the management of cancer resistance and metastasis. Hybrid therapy can affect several cellular targets involved in carcinogenesis with a lessening of adverse effects. Therefore, the current study aims to assemble, and optimize a hybrid of gefitinib (GFT) and simvastatin (SIM)-loaded nanostructured lipid carrier (GFT/SIM-NLC) to combat metastatic and drug-resistant breast cancer. GFT/SIM-NLC cargos were prepared using design of experiments to investigate the impact of poloxamer-188 and fatty acids concentrations on the physicochemical and pharmaceutical behavior properties of NLC. Additionally, the biosafety of the prepared GFT/SIM-NLC was studied using a fresh blood sample. Afterward, the optimized formulation was subjected to an MTT assay to study the cytotoxic activity of GFT/SIM-NLC compared to free GFT/SIM using an MCF-7 cell line as a surrogate model for breast cancer. The present results revealed that the particle size of the prepared NLC ranged from (209 to 410 nm) with a negative zeta potential value ranging from (-17.2 to -23.9 mV). Moreover, the optimized GFT/SIM-NLC formulation showed favorable physicochemical properties and promising lymphatic delivery cargos. A biosafety study indicates that the prepared NLC has a gentle effect on erythrocyte hemolysis. Cytotoxicity studies revealed that GFT/SIM-NLC enhanced the killing of the MCF-7 cell line compared to free GFT/SIM. This study concluded that the hybrid therapy of GFT/SIM-NLC is a potential approach to combat metastatic and drug-resistant breast cancer.

[1]  F. Alanazi,et al.  The chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers. , 2023, Current drug delivery.

[2]  A. Eid,et al.  Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations , 2023, Cancer Cell International.

[3]  F. Alanazi,et al.  Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons , 2023, The Journal of Membrane Biology.

[4]  Xiaojia Chen,et al.  Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer , 2023, Journal of Drug Delivery Science and Technology.

[5]  Wajhul Qamar,et al.  Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer , 2023, Molecules.

[6]  S. Attia,et al.  TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies. , 2023, Colloids and surfaces. B, Biointerfaces.

[7]  F. Alanazi,et al.  SLN Mediate Active Delivery of Gefitinib into A549 Cell Line: Optimization, Biosafety, and Cytotoxicity Studies , 2022, Drug Delivery Letters.

[8]  M. Darvish,et al.  Simvastatin-loaded PCL/PEG nanofibrous scaffold: A prospective approach for suppression 5-fluorouracil resistance in MKN-45 gastric cancer cells , 2022, Journal of Drug Delivery Science and Technology.

[9]  Shun-Fu Chang,et al.  Suppression of SREBP-1 Expression by Simvastatin Decreases Visfatin-Induced Chemoresistance to Sunitinib in Human Renal Carcinoma 786-O Cells , 2022, Life.

[10]  A. Shahba,et al.  Combined Ramipril and Black Seed Oil Dosage Forms Using Bioactive Self-Nanoemulsifying Drug Delivery Systems (BIO-SNEDDSs) , 2022, Pharmaceuticals.

[11]  Walaa A. El-Dakroury,et al.  Design, Characterization and In Vivo Performance of Solid Lipid Nanoparticles (SLNs)-Loaded Mucoadhesive Buccal Tablets for Efficient Delivery of Lornoxicam in Experimental Inflammation. , 2022, International journal of pharmaceutics.

[12]  F. Alanazi,et al.  PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer , 2022, International journal of nanomedicine.

[13]  F. Alanazi,et al.  Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line , 2022, AAPS PharmSciTech.

[14]  Hui-jun Jiang,et al.  Drug-loaded oleic-acid grafted mesoporous silica nanoparticles conjugated with α-lactalbumin resembling BAMLET-like anticancer agent with improved biocompatibility and therapeutic efficacy , 2022, Materials today. Bio.

[15]  E. Cione,et al.  Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role , 2022, Pharmaceuticals.

[16]  B. Luo,et al.  Long noncoding RNA CCAT2 reduces chemosensitivity to 5‐fluorouracil in breast cancer cells by activating the mTOR axis , 2022, Journal of cellular and molecular medicine.

[17]  S. M. Naghib,et al.  A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment , 2022, Scientific reports.

[18]  H. Hayashi,et al.  Statin as a therapeutic agent in gastroenterological cancer , 2022, World journal of gastrointestinal oncology.

[19]  L. P. Cardoso,et al.  Nanostructured lipid carriers for delivery of free phytosterols: Effect of lipid composition and chemical interesterification on physical stability , 2022, Colloids and Surfaces A: Physicochemical and Engineering Aspects.

[20]  B. Tekwani,et al.  Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis , 2021, AAPS PharmSciTech.

[21]  L. Ouyang,et al.  Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions , 2021, Acta pharmaceutica Sinica. B.

[22]  V. Préat,et al.  Quality-by-Design-Based Development of a Voxelotor Self-Nanoemulsifying Drug-Delivery System with Improved Biopharmaceutical Attributes , 2021, Pharmaceutics.

[23]  Xin-Yang He,et al.  Statins: a repurposed drug to fight cancer , 2021, Journal of experimental & clinical cancer research : CR.

[24]  A. Hussain,et al.  Formulation, In Vitro and In Vivo Evaluation of Gefitinib Solid Dispersions Prepared Using Different Techniques , 2021, Processes.

[25]  E. A. Leite,et al.  The potential use of simvastatin for cancer treatment: A review. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[26]  C. Jeong,et al.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance , 2021, Pharmaceuticals.

[27]  Wei Wu,et al.  An update on oral drug delivery via intestinal lymphatic transport , 2021, Acta pharmaceutica Sinica. B.

[28]  F. Shakeel,et al.  Solubilization and thermodynamic properties of simvastatin in various micellar solutions of different non-ionic surfactants: Computational modeling and solubilization capacity , 2021, PloS one.

[29]  M. Shiro,et al.  Study of the physicochemical properties of drugs suitable for administration using a lymphatic drug delivery system. , 2021, Cancer science.

[30]  A. Samy,et al.  Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability , 2020, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[31]  Sebastián Scioli Montoto,et al.  Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects , 2020, Frontiers in Molecular Biosciences.

[32]  N. M. Raghavendra,et al.  Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis , 2020 .

[33]  K. El-Say,et al.  Development of Pomegranate Extract-Loaded Solid Lipid Nanoparticles: Quality by Design Approach to Screen the Variables Affecting the Quality Attributes and Characterization , 2020, ACS omega.

[34]  P. Shah,et al.  Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition , 2020, Drug Delivery and Translational Research.

[35]  M. Loda,et al.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. , 2020, Advanced drug delivery reviews.

[36]  Wajhul Qamar,et al.  Centaurea bruguierana inhibits cell proliferation, causes cell cycle arrest, and induces apoptosis in human MCF-7 breast carcinoma cells , 2020, Molecular Biology Reports.

[37]  A. Sikorski,et al.  Attempts to use statins in cancer therapy: An update , 2020, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[38]  Yongzhuo Huang,et al.  Combination therapy based on nano codelivery for overcoming cancer drug resistance , 2020 .

[39]  Cooper J. Galvin,et al.  Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan , 2020, Cancer science.

[40]  R. Longuespée,et al.  Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy , 2020, Cancers.

[41]  S. Souto,et al.  Sucupira Oil-Loaded Nanostructured Lipid Carriers (NLC): Lipid Screening, Factorial Design, Release Profile, and Cytotoxicity , 2020, Molecules.

[42]  S. Mohan,et al.  Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro , 2020, Drug delivery.

[43]  K. Reddy,et al.  Formulation, in-vitro and in-vivo pharmacokinetic evaluation of simvastatin nanostructured lipid carrier loaded transdermal drug delivery system , 2019, Future Journal of Pharmaceutical Sciences.

[44]  J. Windsor,et al.  Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties. , 2019, Molecular pharmaceutics.

[45]  M. Kariduraganavar,et al.  Co-delivery of paclitaxel and curcumin to foliate positive cancer cells using Pluronic-coated iron oxide nanoparticles , 2019, Progress in Biomaterials.

[46]  J. Swinnen,et al.  Lipid metabolism in cancer cells under metabolic stress , 2019, British Journal of Cancer.

[47]  F. Rossi,et al.  Ucuùba (Virola surinamensis) Fat-Based Nanostructured Lipid Carriers for Nail Drug Delivery of Ketoconazole: Development and Optimization Using Box-Behnken Design , 2019, Pharmaceutics.

[48]  A. Zeb,et al.  Simvastatin‐loaded solid lipid nanoparticles for enhanced anti‐hyperlipidemic activity in hyperlipidemia animal model , 2019, International journal of pharmaceutics.

[49]  T. Rachner,et al.  Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells , 2019, Cell Death & Disease.

[50]  I. Casaburi,et al.  Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment , 2019, Front. Endocrinol..

[51]  Z. Oltvai,et al.  Statin drugs to reduce breast cancer recurrence and mortality , 2018, Breast Cancer Research.

[52]  Yakun Wan,et al.  Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M -Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. , 2018, Small.

[53]  Mohamed Alfateh Badawy,et al.  DOE, formulation, and optimization of Repaglinide nanostructured lipid carriers , 2018, Journal of Applied Pharmaceutical Science.

[54]  Dhiraj Kumar,et al.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges , 2018, Molecular Cancer.

[55]  V. Junyaprasert,et al.  Effect of binary solid lipid matrix of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles (SLN) for dermal delivery. , 2017, Journal of colloid and interface science.

[56]  T. Rades,et al.  Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations , 2017, The AAPS Journal.

[57]  Han‐Gon Choi,et al.  Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles , 2016, AAPS PharmSciTech.

[58]  M. Riyazuddin,et al.  Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity , 2016, Scientific Reports.

[59]  S. Miyamoto,et al.  Effect of Ouratea sp. butter in the crystallinity of solid lipids used in nanostructured lipid carriers (NLCs) , 2016, Journal of Thermal Analysis and Calorimetry.

[60]  D. Graham,et al.  Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. , 2015, World journal of gastroenterology.

[61]  G. Harisa,et al.  Simvastatin nanolipid carriers decreased hypercholesterolemia induced cholesterol inclusion and phosphatidylserine exposure on human erythrocytes , 2015 .

[62]  G. Zhai,et al.  Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation , 2015 .

[63]  Y. Darwis,et al.  Advanced drug delivery to the lymphatic system: lipid-based nanoformulations , 2013, International journal of nanomedicine.

[64]  Peter Goos,et al.  I-Optimal Versus D-Optimal Split-Plot Response Surface Designs , 2012 .

[65]  F. Plakogiannis,et al.  Development and oral bioavailability assessment of a supersaturated self‐microemulsifying drug delivery system (SMEDDS) of albendazole , 2010, The Journal of pharmacy and pharmacology.

[66]  F. Alanazi,et al.  Engineering of exosomes: Steps towards green production of drug delivery systems. , 2019, Current drug targets.

[67]  Xinsheng Peng,et al.  Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design , 2011 .